Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine

PURPOSE: An autologous tumor vaccine already used successfully in the immune therapy of renal cell carcinoma was investigated in detail. The evaluation of potential tumor markers should allow for the assessment of potency according to pharmaceutical regulations. METHODS: A panel of 36 tumor-associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wittke, Stefan, Baxmann, Susann, Fahlenkamp, Dirk, Kiessig, Stephan T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743638/
https://www.ncbi.nlm.nih.gov/pubmed/26889089
http://dx.doi.org/10.2147/OTT.S92182
_version_ 1782414387039961088
author Wittke, Stefan
Baxmann, Susann
Fahlenkamp, Dirk
Kiessig, Stephan T
author_facet Wittke, Stefan
Baxmann, Susann
Fahlenkamp, Dirk
Kiessig, Stephan T
author_sort Wittke, Stefan
collection PubMed
description PURPOSE: An autologous tumor vaccine already used successfully in the immune therapy of renal cell carcinoma was investigated in detail. The evaluation of potential tumor markers should allow for the assessment of potency according to pharmaceutical regulations. METHODS: A panel of 36 tumor-associated antigens and cellular marker proteins was characterized in a total of 133 tumor cell lysates by methods such as ELISA, Western blots, and topological proteomics. The induction of tumor-associated antigen-specific antibodies was demonstrated by immunization in mice. RESULTS: Tumor heterogeneity was demonstrated: none of the tumor-associated antigens investigated were detectable in each tumor lysate. In parallel, the coincidental presence of potential danger signals was shown for HSP-60 and HSP-70. The presence of both antigen and danger signal allowed a successful induction of an immune response in a murine model. CONCLUSION: The verified tumor heterogeneity indicates the need for a multi-epitope approach for the successful immunotherapy in renal cell carcinoma.
format Online
Article
Text
id pubmed-4743638
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-47436382016-02-17 Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine Wittke, Stefan Baxmann, Susann Fahlenkamp, Dirk Kiessig, Stephan T Onco Targets Ther Original Research PURPOSE: An autologous tumor vaccine already used successfully in the immune therapy of renal cell carcinoma was investigated in detail. The evaluation of potential tumor markers should allow for the assessment of potency according to pharmaceutical regulations. METHODS: A panel of 36 tumor-associated antigens and cellular marker proteins was characterized in a total of 133 tumor cell lysates by methods such as ELISA, Western blots, and topological proteomics. The induction of tumor-associated antigen-specific antibodies was demonstrated by immunization in mice. RESULTS: Tumor heterogeneity was demonstrated: none of the tumor-associated antigens investigated were detectable in each tumor lysate. In parallel, the coincidental presence of potential danger signals was shown for HSP-60 and HSP-70. The presence of both antigen and danger signal allowed a successful induction of an immune response in a murine model. CONCLUSION: The verified tumor heterogeneity indicates the need for a multi-epitope approach for the successful immunotherapy in renal cell carcinoma. Dove Medical Press 2016-01-27 /pmc/articles/PMC4743638/ /pubmed/26889089 http://dx.doi.org/10.2147/OTT.S92182 Text en © 2016 Wittke et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Wittke, Stefan
Baxmann, Susann
Fahlenkamp, Dirk
Kiessig, Stephan T
Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine
title Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine
title_full Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine
title_fullStr Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine
title_full_unstemmed Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine
title_short Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine
title_sort tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743638/
https://www.ncbi.nlm.nih.gov/pubmed/26889089
http://dx.doi.org/10.2147/OTT.S92182
work_keys_str_mv AT wittkestefan tumorheterogeneityasarationaleforamultiepitopeapproachinanautologousrenalcellcancertumorvaccine
AT baxmannsusann tumorheterogeneityasarationaleforamultiepitopeapproachinanautologousrenalcellcancertumorvaccine
AT fahlenkampdirk tumorheterogeneityasarationaleforamultiepitopeapproachinanautologousrenalcellcancertumorvaccine
AT kiessigstephant tumorheterogeneityasarationaleforamultiepitopeapproachinanautologousrenalcellcancertumorvaccine

Ejemplares similares